Stop advertising claims of 'Ayurvedic COVID-19 medicine' until verification, Ayush ministry tells Ramdev's Patanjali Ayurveda
Earlier on Tuesday, Patanjali founder Ramdev said that the medicines, 'Coronil and Swasari', 'were developed based on research and trials on 280 patients across the country,' NDTV reported.
Hours after Ramdev's Patanjali Ayurveda claimed that they have a "ayurvedic COVID-19 medicine", the Centre issued a statement demanding details of the said medicine. Patanjali Ayurveda Ltd launched the product on Tuesday. In a statement, the Ministry of AYUSH instructed Patanjali to refrain from advertising or publicising such claims until they were examined.
"Ministry of AYUSH has taken cognizance of the news being recently flashed in the media about Ayurvedic medicines developed for treatment of COVID-19 by Patanjali Ayurved. Facts of the claim and details of the stated scientific study are not known to the Ministry," the statement said.
A tweet by Patanjali was also deleted by Twitter after Alt News co-founder Sumaiya Shaikh flagged it as "medical misinformation" and referred to the Centre's direction regarding advertising.
Earlier on Tuesday, Patanjali founder Ramdev said that the medicines, 'Coronil and Swasari', "were developed based on research and trials on 280 patients across the country," NDTV reported.
The Ayush ministry demanded "at the earliest", details of the name and composition of the medicines being claimed for COVID treatment, "site(s)/hospital(s), where the research study was conducted for COVID-19, the protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study(ies)."
During the launch, Ramdev said, "The whole country and the world was waiting for medicine or vaccine for corona. We are proud to announce that the first Ayurvedic, clinically controlled trial-based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS."
"We are launching COVID-19 medicines Coronil and Swasari today. We conducted two trials of these, first clinical controlled study, which took place in Delhi, Ahmedabad, among many other cities. Under this 280 patients were included and 100 per cent of those recovered. We were able to control Corona and its complications in this. After this the all-important clinical control trial was conducted," he claimed.
The company also said that it had collaborated with National Institute of Medical Sciences or NIMS University, Jaipur.
"With the help of NIMS, Jaipur we conducted the clinical control study on 95 patients. The biggest thing which came out of this is that within three days 69 per cent patients recovered and became negative from positive (cases) and within seven days 100 per cent of them became negative," said Ramdev.
With inputs from agencies
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
The task force of nine senior doctors was formed on 13 April in view of increasing number of coronavirus cases and deaths in the state, especially in Mumbai.
'COVID-19 crisis worse than war of Mahabharata': Shiv Sena targets PM for claiming pandemic would end in 21 days
The fight against COVID-19 is more difficult than the mythological war of Mahabharata, said Shiv Sena, adding that the battle against the pandemic will continue till 2021 as the vaccine won't be available before that.
COVAXIN controversy: Doctors in trial sites chosen by ICMR say human trials can’t be fast forwarded, anticipate 6-month observation period
Hyderabad-based Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of COVAXIN last week. The vaccine has been developed in collaboration with the ICMR and National Institute of Virology in Pune.